All posts tagged ross camidge

  • Brigatinib first drug to offer over 1-year control of ALK-positive lung cancer post-crizotinib

    Clinical trial results lead to FDA approval of brigatinib as a second-line therapy for ALK-positive non-small cell lung cancer.